MiR-1203 is involved in hepatocellular carcinoma metastases and indicates a poor prognosis

Shi, Jianguo; Li, X; Hu, Yue; Zhang, F; Lv, Xuejun; Zhang, X; Chen, Q; Hu, Shiqi

doi:10.4149/neo_2019_190414n328

Cited by 13 publications

(5 citation statements)

References 33 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…The average number of differential miRNAs per cancer was 7 ± 1.08, with hsa-miR-125a-3p, hsa-miR-887-3p, and hsa-miR-1203 being differentially expressed in all 13 cancer types. Studies reported that these three miR-NAs are associated with cancerogenesis and progression in multiple cancers [22][23][24]. This result suggests common alterations in serum miRNAs in different cancer types.…”

Section: Low Cancer Specificity Of 5-mirpairs For Gliomamentioning

confidence: 85%

Construct of qualitative diagnostic biomarkers specific for glioma by pairing serum microRNAs

Luo

et al. 2023

BMC Genomics

View full text Add to dashboard Cite

Background Serum microRNAs (miRNAs) are promising non-invasive biomarkers for diagnosing glioma. However, most reported predictive models are constructed without a large enough sample size, and quantitative expression levels of their constituent serum miRNAs are susceptible to batch effects, decreasing their clinical applicability. Methods We propose a general method for detecting qualitative serum predictive biomarkers using a large cohort of miRNA-profiled serum samples (n = 15,460) based on the within-sample relative expression orderings of miRNAs. Results Two panels of miRNA pairs (miRPairs) were developed. The first was composed of five serum miRPairs (5-miRPairs), reaching 100% diagnostic accuracy in three validation sets for distinguishing glioma and non-cancer controls (n = 436: glioma = 236, non-cancers = 200). An additional validation set without glioma samples (non-cancers = 2611) showed a predictive accuracy of 95.9%. The second panel included 32 serum miRPairs (32-miRPairs), reaching 100% diagnostic performance in training set on specifically discriminating glioma from other cancer types (sensitivity = 100%, specificity = 100%, accuracy = 100%), which was reproducible in five validation datasets (n = 3387: glioma = 236, non-glioma cancers = 3151, sensitivity> 97.9%, specificity> 99.5%, accuracy> 95.7%). In other brain diseases, the 5-miRPairs classified all non-neoplastic samples as non-cancer, including stroke (n = 165), Alzheimer’s disease (n = 973), and healthy samples (n = 1820), and all neoplastic samples as cancer, including meningioma (n = 16), and primary central nervous system lymphoma samples (n = 39). The 32-miRPairs predicted 82.2 and 92.3% of the two kinds of neoplastic samples as positive, respectively. Based on the Human miRNA tissue atlas database, the glioma-specific 32-miRPairs were significantly enriched in the spinal cord (p = 0.013) and brain (p = 0.015). Conclusions The identified 5-miRPairs and 32-miRPairs provide potential population screening and cancer-specific biomarkers for glioma clinical practice.

show abstract

Section: Low Cancer Specificity Of 5-mirpairs For Gliomamentioning

confidence: 85%

Construct of qualitative diagnostic biomarkers specific for glioma by pairing serum microRNAs

Luo

et al. 2023

BMC Genomics

View full text Add to dashboard Cite

show abstract

“… 66 In a similar study, miR-1203 suppresses SOCS3 in HCC by binding to its 3′-UTR region, which promotes over-phosphorylation of STAT3, increased HCC cell proliferation and invasion, hepatic fibrosis, and tumor aggressiveness. 67 Furthermore, miR-6887-5p overexpression causes suppression of signal transduction in transforming growth factor beta (TGF-β), mediated by Smad3. This leads to dysregulation of diverse cellular processes such as cell proliferation, differentiation, migration and apoptosis which promotes the development of multiple cancers such as CC, BC, ovarian cancer, and pancreatic cancer.…”

Section: Discussionmentioning

confidence: 99%

“…These miRNAs have been reported previously to cause various different cancers such as, HCC, prostate cancer, pancreatic cancer, and ovarian cancer. 61 , 67 , 68 , 71 Hence, it is suggested that anti-miR drugs should be developed that can target these oncomiRs and downregulate their expression, which may lead to normal expression of the SOCS3. 72 …”

Section: Discussionmentioning

confidence: 99%

MicroRNAs Regulate Tumorigenesis by Downregulating SOCS3 Expression: An In silico Approach

Al-Asadi,

Mansour,

Ataimish

et al. 2023

Bioinform Biol Insights

View full text Add to dashboard Cite

Tumor microenvironment is characterized by the occurrence of significant changes due to disrupted signaling pathways that affect a broad spectrum of cellular activities such as proliferation, differentiation, signaling, invasiveness, migration, and apoptosis. Similarly, a downregulated suppressor of cytokine signaling 3 (SOCS3) promotes increased JAK/STAT function due to aberrant cytokine signaling, which results in increased cell proliferation, differentiation, and migration. Multiple carcinomas including breast cancer, prostate cancer, hepatocellular carcinoma, pancreatic cancer, and colorectal cancer involve the disruption of SOCS3 expression due to microRNA overexpression. MicroRNAs are small, conserved, and non-coding RNA molecules that regulate gene expression through post-transcriptional inhibition and mRNA destabilization. The aim of this study was to identify putative microRNAs that interact with SOCS3 and downregulate its expression. In this study, miRWalk, TargetScan, and miRDB were used to identify microRNAs that interact with SOCS3, whereas RNA22 was utilized to identify the binding sites of 238 significant microRNAs. The tertiary structures of shortlisted microRNAs and SOCS3 regions were predicted through MC Sym and RNAComposer, respectively. For molecular docking, HDOCK was used, which predicted 80 microRNA-messengerRNA complexes and the interactions of the top 5 shortlisted complexes were assessed. The complexes were shortlisted on the basis of least binding affinity score and maximum confidence score. This study identifies the interactions of known (miR-203a-5p) and novel (miR-6756-5p, miR-6732-5p, miR-1203, miR-6887-5p) microRNAs with SOCS3 regions due to their maximum interactions. Identifying the interactions of these microRNAs with SOCS3 will significantly advance the understanding of oncomiRs (miRNAs that are associated with cancer development) in tumor development due to their influence on SOCS3 expression. These insights will assist in future studies to understand the significance of miRNA-SOCS3-associated tumor development and progression.

show abstract

“…MiR-1203 has been identified as a potential serum biomarker for prostate cancer [ 53 ] and a predictor of prognosis for hepatocellular carcinoma [ 54 ].…”

Section: Discussionmentioning

confidence: 99%

A novel microRNA signature for the detection of melanoma by liquid biopsy

et al. 2022

View full text Add to dashboard Cite

Background Melanoma is the deadliest form of skin cancer and metastatic disease is associated with a significant survival rate drop. There is an urgent need for consistent tumor biomarkers to scale precision medicine and reduce cancer mortality. Here, we aimed to identify a melanoma-specific circulating microRNA signature and assess its value as a diagnostic tool. Methods The study consisted of a discovery phase and two validation phases. Circulating plasma extracellular vesicles (pEV) associated microRNA profiles were obtained from a discovery cohort of metastatic melanoma patients and normal subjects as controls. A pEV-microRNA signature was obtained using a LASSO penalized logistic regression model. The pEV-microRNA signature was subsequently validated both in a publicly available dataset and in an independent internal cohort. Results We identified and validated in three independent cohorts a panel of melanoma-specific circulating microRNAs that showed high accuracy in differentiating melanoma patients from healthy subjects with an area under the curve (AUC) of 1.00, 0.94 and 0.75 respectively. Investigation of the function of the pEV-microRNA signature evidenced their possible immune suppressive role in melanoma patients. Conclusions We demonstrate that a blood test based on circulating microRNAs can non-invasively detect melanoma, offering a novel diagnostic tool for improving standard care. Moreover, we revealed an immune suppressive role for melanoma pEV-microRNAs.

show abstract

MiR-1203 is involved in hepatocellular carcinoma metastases and indicates a poor prognosis

Cited by 13 publications

References 33 publications

Construct of qualitative diagnostic biomarkers specific for glioma by pairing serum microRNAs

Construct of qualitative diagnostic biomarkers specific for glioma by pairing serum microRNAs

MicroRNAs Regulate Tumorigenesis by Downregulating SOCS3 Expression: An In silico Approach

A novel microRNA signature for the detection of melanoma by liquid biopsy

Contact Info

Product

Resources

About